Jorge Quintana, MD
Psychiatry · Rahway, NJNPI 1326103128
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 1,228 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,228 payments — averaging $13.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Neurocrine Biosciences, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Sunovion Pharmaceuticals Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Axsome Therapeutics, Inc.$925
- plus $7K from 27 others
What the payments were for
- Food & beverage$16,945100%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 216 | $2,614 |
| Neurocrine Biosciences, Inc. | 101 | $2,024 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 116 | $1,856 |
| Sunovion Pharmaceuticals Inc. | 101 | $1,157 |
| Otsuka America Pharmaceutical, Inc. | 110 | $1,086 |
| Axsome Therapeutics, Inc. | 57 | $925 |
| Teva Pharmaceuticals USA, Inc. | 75 | $849 |
| Lundbeck LLC | 67 | $818 |
| Alkermes, Inc. | 33 | $705 |
| Takeda Pharmaceuticals U.S.A., Inc. | 53 | $686 |
| Bausch Health US, LLC | 45 | $507 |
| Jazz Pharmaceuticals Inc. | 27 | $478 |
| Vanda Pharmaceuticals Inc. | 38 | $448 |
| Almatica Pharma LLC | 30 | $424 |
| Corium, LLC | 35 | $397 |
| Idorsia Pharmaceuticals US Inc | 24 | $311 |
| Tris Pharma Inc | 21 | $309 |
| Supernus Pharmaceuticals, Inc. | 11 | $293 |
| Johnson & Johnson | 13 | $192 |
| Harmony Biosciences LLC | 2 | $137 |
| Avanir Pharmaceuticals, Inc. | 8 | $117 |
| Noven Therapeutics, LLC | 8 | $112 |
| E.r. Squibb & Sons, L.L.C. | 5 | $87 |
| Alfasigma USA, Inc. | 6 | $75 |
| Arbor Pharmaceuticals, Inc. | 5 | $72 |
| Merck | 5 | $69 |
| Eisai Inc. | 5 | $65 |
| Luye Pharma (USA) Ltd. | 3 | $47 |
| Neos Therapeutics, LP | 2 | $26 |
| Adlon Therapeutics L.p. | 2 | $26 |
| Shire North American Group Inc | 2 | $24 |
| Braeburn Inc. | 1 | $16 |
| Ironshore Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,966 in reported general payments places this provider in the 95th percentile of 1,119 psychiatry providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 55 | $438,522 |
| RexultiBrexpiprazole | 121 | $196,978 |
| VraylarCariprazine Hcl | 86 | $130,736 |
| CaplytaLumateperone Tosylate | 61 | $110,542 |
| AtivanLorazepam | 12 | $69,508 |
| BelsomraSuvorexant | 121 | $59,847 |
| LybalviOlanzapine/Samidorphan Malate | 35 | $51,899 |
| Invega SustennaPaliperidone Palmitate | 14 | $37,983 |
| Lurasidone Hcl | 158 | $37,723 |
| TrintellixVortioxetine Hydrobromide | 39 | $36,314 |
| XanaxAlprazolam | 42 | $30,101 |
| Abilify MaintenaAripiprazole | 11 | $30,081 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 333 | $25,166 |
| Seroquel XrQuetiapine Fumarate | 22 | $19,209 |
| Quetiapine Fumarate | 702 | $15,338 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $2,024 | $438,52255 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,086 | $227,059132 claims |
| AbbVieVraylar, Viibryd | $2,614 | $135,28599 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,856 | $110,54261 claims |
| MerckBelsomra | $69 | $59,847121 claims |
| Alkermes, Inc.Lybalvi | $705 | $51,89935 claims |
| Johnson & JohnsonInvega Sustenna | $192 | $37,98314 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $686 | $36,31439 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $311 | $14,04529 claims |
| Eisai Inc.Dayvigo | $65 | $7,67219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,119 psychiatry providers in New Jersey.
Other psychiatry in Rahway
- Marc CantillonLivingston$522K
- Robert BransfieldRed Bank$415K
- Erika ConcepcionLong Branch$354K
- Leon RosenbergCherry Hill$257K
- Lloyd AlceraMarlton$187K
- Gary SmallHackensack$170K
- Shankar SrinivasanParsippany$155K
- Matthew PiteraToms River$153K
- Boris BorodulinEast Brunswick$116K
- Anthony RostainCamden$110K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.